Cash, cash equivalents and marketable securities were $588.9 million as of September 30, 2025, compared to $621.2 million as of June 30, 2025. In October, Apogee completed a $345 million underwritten public equity offering resulting in $913 million cash, cash equivalents and marketable securities on a pro forma basis as of September 30, 2025. Based on current operating plans, Apogee expects its existing total cash will enable the company to fund its operating expenses into the second half of 2028.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics price target raised to $70 from $60 at RBC Capital
- Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy
- Apogee Therapeutics initiated with a Buy at Craig-Hallum
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know